மருந்துகள் சீனா இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் சீனா இணை லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் சீனா இணை லிமிடெட் Today - Breaking & Trending Today

CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference

Time: 9:30 AM (EST)
Webcast or external link of the company presentations will be available under Events & Presentations in the Investors Relations section of CASI s website. Archived replays will be available for approximately 30 days following the event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company s China-based regulatory and commercial competencies and its global drug development expertise. The Company s operations in China are conducted through its wholly-owned sub ....

United States , Pharmaceuticals China Co Ltd , Pharmaceuticals Inc , Chief Executive Officer , Jefferies Virtual Healthcare , Casi Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , மருந்துகள் சீனா இணை லிமிடெட் , மருந்துகள் இன்க் , தலைமை நிர்வாகி அதிகாரி , ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் ,

CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021

CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Pharmaceuticals China Co Ltd , Pharmaceuticals Inc , Acrotech Biopharma , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , மருந்துகள் சீனா இணை லிமிடெட் , மருந்துகள் இன்க் ,

CASI Pharmaceuticals To Host Business Update Call March 12, 2021

CASI Pharmaceuticals To Host Business Update Call March 12, 2021
News provided by
Share this article
Share this article
ROCKVILLE, Md. and BEIJING, March 11, 2021 /PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call at 8:00 a.m. ET on Friday, March 12, 2020.
On the call, CASI s Chairman & CEO will provide an update on recent business developments and review upcoming milestones. The conference call can be accessed by dialing (877) 405-1224 (U.S.), (86) 400-120-2840 (China), (800) 965-561 (Hong Kong) to listen to the live presentation. The live webcast can be accessed at the following link: https://78449.themediaframe.com/dataconf/productusers/casi/mediaframe/44098/indexl.html ....

United States , Hong Kong , Weihao Xu , Jennifer Porcelli , Pharmaceuticals China Co Ltd , Investor Center , Pharmaceuticals Inc , Private Securities Litigation Reform Act , Casi Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , ஜெனிபர் போர்செல்லி , மருந்துகள் சீனா இணை லிமிடெட் , முதலீட்டாளர் மையம் , மருந்துகள் இன்க் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma

Share this article
Share this article
ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ( BioInvent ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin s Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time (5:30 p.m. CET).
The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin s Lymphoma for whom current treatment options are very limited. ....

United States , Martin Welschof , Mary Ann Chang , Jennifer Porcelli , Bioinvent International , Bioinvent International Ab , Pharmaceuticals China Co Ltd , Lund University , Nordic Lymphoma Group , Pharmaceuticals Inc , Key Opinion Leader , Mats Jerkeman , Clinical Oncology , Swedish Lymphoma Register , Greater China , Private Securities Litigation Reform Act , Ann Chang , Casi Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , மேரி ஆண்டு சாங் , ஜெனிபர் போர்செல்லி , மருந்துகள் சீனா இணை லிமிடெட் , லண்ட் பல்கலைக்கழகம் , நோர்டிக் லிம்போமா குழு , மருந்துகள் இன்க் , விசை கருத்து தலைவர் ,

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

Share this article
Share this article
ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation ( Breakthrough Designation ) to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas.
The Breakthrough Designation for CNCT19 was granted based on initial data from the ongoing single arm, open-label, non-randomized, dose-escalation, Phase I study designed to determine the safety and efficacy of CNCT19 in B-ALL. ....

United States , Jennifer Porcelli , Institute Of Hematology , Chinese Center , China National Medical Products Association , Pharmaceuticals China Co Ltd , Juventas Cell Therapy Ltd , Pharmaceuticals Inc , Chinese Academy Of Medical Sciences , Drug Evaluation , Breakthrough Therapy Designation , Juventas Cell Therapy , Breakthrough Designation , Drug Registration Regulation , Receiving Breakthrough Designation , Cell Therapy , Tianjin City , Chinese Academy , Medical Sciences , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஜெனிபர் போர்செல்லி , நிறுவனம் ஆஃப் ஹீமாட்டாலஜி , சீன மையம் , சீனா தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம் , மருந்துகள் சீனா இணை லிமிடெட் ,